News

Cambridge, UK, November 13, 2024 –Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI-driven drug discovery platform. Under the agreement, Sanofi will provide data related to a late stage discontinued asset that is being considered for out-licensing. … Continued

Why Fast Track designation Matters The Fast Track designation is awarded by the FDA to facilitate the development and review of drugs that treat serious conditions and fill unmet medical needs. For our team, it means increased interaction with FDA experts throughout the development process, allowing us to gain early feedback on crucial steps, such … Continued